[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 43 of about 43
1. Hayashi M, Tsuchiya H, Yamamoto N, Karita M, Shirai T, Nishida H, Takeuchi A, Tomita K: Caffeine-potentiated chemotherapy for metastatic carcinoma and lymphoma of bone and soft tissue. Anticancer Res; 2005 May-Jun;25(3c):2399-405
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caffeine-potentiated chemotherapy for metastatic carcinoma and lymphoma of bone and soft tissue.
  • BACKGROUND: We previously reported that caffeine-potentiated chemotherapy induced significantly good response in patients with musculoskeletal sarcomas.
  • In that series, patients with metastatic carcinoma or lymphoma were treated with caffeine-potentiated chemotherapy.
  • PATIENTS AND METHODS: Five patients with metastatic carcinoma or lymphoma were treated with caffeine-potentiated chemotherapy.
  • RESULTS: Primary tumors were diagnosed as breast cancer, adenocarcinoma of the lung, clear cell adenocarcinoma of the vagina, diffuse large B-cell lymphoma and gastric cancer.
  • Good responses (gross tumor shrinkage >30%, or histologically >90% necrosis) to chemotherapy were seen in all five patients.
  • Survival time was >1 year in all patients, and three out of five patients presented no evidence of local recurrence or metastasis at the final follow-up.
  • CONCLUSION: Caffeine-potentiated chemotherapy may be of benefit for malignant tumors other than musculoskeletal sarcoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Caffeine / pharmacology. Carcinoma / drug therapy. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Aged. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Drug Synergism. Female. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Male. Middle Aged. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology. Vaginal Neoplasms / drug therapy. Vaginal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Caffeine.
  • Hazardous Substances Data Bank. CAFFEINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16080466.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 3G6A5W338E / Caffeine
  •  go-up   go-down


2. Mader AM, Patrício FR, Rigueiro MP, Lourenço LG: [Analysis of clinicopathological, tumor cell proliferation and apoptosis parameters in adenocarcinoma of the gastric cardia]. Arq Gastroenterol; 2006 Jul-Sep;43(3):184-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of clinicopathological, tumor cell proliferation and apoptosis parameters in adenocarcinoma of the gastric cardia].
  • [Transliterated title] Estudo clínico-patológico, da proliferação celular e da apoptose no adenocarcinoma gástrico da cárdia.
  • MATERIAL AND METHODS: Forty cases of adenocarcinoma of the cardia were studied between 1988 and 2001, with a minimum clinical follow-up of 3 years.
  • Patients were excluded if they had previous chemotherapy or radiotherapy treatment, presented early neoplasia, or died during the operations or for other reasons unrelated to cancer.
  • Gender; age, Laurén and Ming histological type, staging, and the presence or absence of intestinal metaplasia, epithelial dysplasia and Helicobacter pylori in the adjacent mucosa were analyzed.
  • There was predominance of the male gender (72.5%), diffuse histological type (55%) and infiltrative histological type (72.5%), and the more advanced stages (III and IV: 67.5%).
  • There was a positive correlation for intestinal histological type with PCNA and apoptotic indices, in 10 high power fields.
  • CONCLUSIONS: Adenocarcinoma of the cardia predominated in male adults of mean age 61 years, and the predominant type was diffuse in more advanced stages.
  • Survival in cases of adenocarcinoma of the cardia is still low.
  • Both age and apoptosis were independent prognostic factors in cancer of the cardia.
  • [MeSH-major] Adenocarcinoma / pathology. Apoptosis. Cardia / pathology. Cell Proliferation. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17160232.001).
  • [ISSN] 0004-2803
  • [Journal-full-title] Arquivos de gastroenterologia
  • [ISO-abbreviation] Arq Gastroenterol
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Proliferating Cell Nuclear Antigen
  •  go-up   go-down


3. Peterson WL: Review article: Helicobacter pylori and gastric adenocarcinoma. Aliment Pharmacol Ther; 2002 Mar;16 Suppl 1:40-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Review article: Helicobacter pylori and gastric adenocarcinoma.
  • Gastric adenocarcinoma is still the second most common cause of death from cancer, even though it is on the decline in developed countries.
  • Although H. pylori gastritis appears to be a necessary antecedent to the development of gastric adenocarcinoma, it is not a sufficient factor in and of itself.
  • Patients with antral predominant gastritis seem protected from the disease, while patients with pangastritis are predisposed to both diffuse- and intestinal-type adenocarcinoma.
  • Development of a vaccine against H. pylori might yield promising results in decreasing the incidence of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / etiology. Helicobacter Infections / complications. Helicobacter pylori / isolation & purification. Stomach Neoplasms / etiology
  • [MeSH-minor] Animals. Disease Models, Animal. Drug Therapy, Combination. Gerbillinae. Humans

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11849127.001).
  • [ISSN] 0269-2813
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 34
  •  go-up   go-down


Advertisement
4. Matsubara J, Yamada Y, Hirashima Y, Takahari D, Okita NT, Kato K, Hamaguchi T, Shirao K, Shimada Y, Shimoda T: Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer. Clin Cancer Res; 2008 May 15;14(10):3022-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer.
  • PURPOSE: Expression levels of insulin-like growth factor type 1 receptor (IGF-IR), epidermal growth factor receptor (EGFR), and HER2 expressions have been linked to clinical outcomes in several solid tumors.
  • However, the clinical significance of these biomarkers in gastric cancer (GC) remains unclear.
  • EXPERIMENTAL DESIGN: The study group comprised 87 patients who underwent gastrectomy at National Cancer Center Hospital and subsequently received chemotherapy for recurrent or residual tumors.
  • Multivariate survival analysis showed that IGF-IR-positive expression [hazard ratio (HR) 2.14, 95% confidence interval (95% CI) 1.20-3.82; P = 0.01], performance status 1 or 2 (HR 1.83, 95% CI 1.15-2.91; P = 0.01), and diffuse type tumors (HR 1.71; 95% CI 1.08-2.70; P = 0.02) were significant predictors of poor survival.
  • CONCLUSIONS: IGF-IR expression in surgical GC specimens, poor performance status, and diffuse type tumors are significant predictors of poor outcomes in patients with GC.
  • [MeSH-major] Biomarkers, Tumor / analysis. Receptor, Epidermal Growth Factor / biosynthesis. Receptor, ErbB-2 / biosynthesis. Receptor, IGF Type 1 / biosynthesis. Stomach Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / metabolism. Adenocarcinoma / mortality. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Female. Gene Expression. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18483367.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2; EC 2.7.10.1 / Receptor, IGF Type 1
  •  go-up   go-down


5. Ott K, Lordick F, Herrmann K, Krause BJ, Schuhmacher C, Siewert JR: The new credo: induction chemotherapy in locally advanced gastric cancer: consequences for surgical strategies. Gastric Cancer; 2008;11(1):1-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The new credo: induction chemotherapy in locally advanced gastric cancer: consequences for surgical strategies.
  • Perioperative chemotherapy in stage II and stage III gastric cancer is now accepted as a standard of care in the Western world.
  • Two randomized phase III studies have shown improved survival for patients with induction chemotherapy followed by surgery compared with surgery alone.
  • It is generally accepted that patients who respond to induction therapy have a significantly improved survival compared with that in nonresponding patients.
  • In adenocarcinomas of the esophagogastric junction (AEG), fluorodeoxyglucose-positron emission tomography (FDG-PET) prospectively was established as a surrogate predicting response and prognosis.
  • The MUNICON (Metabolic response evalUatioN for Individualisation of neoadjuvant Chemotherapy in oesOphageal and oesophagogastric adeNocarcinoma) I study confirmed prospectively the usefulness of early metabolic response evaluation and showed the feasibility of a PET-guided treatment algorithm.
  • These findings are an important step forward in the tailoring of multimodal treatment in accordance with tumor biology.
  • In gastric cancer, we have analyzed FDG-PET in a prospective study.
  • In gastric cancer the issue is more complicated, because about 30% of gastric cancers cannot be visualized with sufficient contrast for quantification.
  • Insufficient FDG uptake is mostly associated with diffuse-type gastric cancer with signet ring cells and mucinous content.
  • Treatment concepts such as immediate resection after only 2 weeks of induction therapy with or without adjuvant treatment could be considered in metabolic nonresponders, or modified chemotherapy regimens, possibly including biologically targeted drugs, could be considered in those with FDG-nonavid tumors.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Neoadjuvant Therapy / methods. Positron-Emission Tomography. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery
  • [MeSH-minor] Contrast Media. Disease Progression. Fluorodeoxyglucose F18. Humans. Neoplasm Staging. Prognosis. Radiopharmaceuticals. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1999 Mar 25;340(12):908-14 [10089184.001]
  • [Cites] Cancer. 2005 Dec 1;104(11):2365-72 [16245310.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Ann Surg. 2007 Oct;246(4):624-8; discussion 628-31 [17893499.001]
  • [Cites] J Clin Oncol. 1999 Aug;17 (8):2403-11 [10561303.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Feb;33(2):148-55 [16228236.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1521-30 [14508841.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):279-86 [11466680.001]
  • [Cites] Radiology. 2006 May;239(2):472-80 [16543584.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12 ):3058-65 [11408502.001]
  • [Cites] J Nucl Med. 2005 Dec;46(12 ):2029-34 [16330567.001]
  • [Cites] Ann Surg. 1999 Mar;229(3):303-8 [10077040.001]
  • [Cites] Cancer. 1993 Oct 1;72(7):2089-97 [8374867.001]
  • [Cites] Lancet Oncol. 2007 Sep;8(9):797-805 [17693134.001]
  • [Cites] Gastric Cancer. 2003;6(3):159-67 [14520529.001]
  • [Cites] Surg Oncol Clin N Am. 2000 Jan;9(1):97-117, vii-viii [10601527.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4692-8 [16966684.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):2307-15 [12796400.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2069-77 [15082726.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4604-10 [14673049.001]
  • [Cites] J Nucl Med. 2005 Oct;46(10 ):1582-8 [16204706.001]
  • [Cites] Ann Surg. 2005 May;241(5):810-7; discussion 817-20 [15849517.001]
  • [Cites] Jpn J Clin Oncol. 2003 Oct;33(10):533-7 [14623923.001]
  • [Cites] Gastric Cancer. 2000 Dec 27;3(3):128-133 [11984725.001]
  • [Cites] Zhonghua Wai Ke Za Zhi. 2006 May 15;44(10 ):661-4 [16784672.001]
  • [Cites] Nucl Med Commun. 2004 Aug;25(8):825-31 [15266178.001]
  • [Cites] World J Surg. 2004 Mar;28(3):247-53 [14961197.001]
  • [Cites] Gastric Cancer. 2006;9(3):192-6 [16952037.001]
  • [Cites] Ann Thorac Surg. 2004 Oct;78(4):1152-60; discussion 1152-60 [15464463.001]
  • [Cites] Cancer. 2005 Jun 1;103(11):2383-90 [15856477.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] Gan To Kagaku Ryoho. 2000 Dec;27(14):2179-84 [11142160.001]
  • [Cites] Cancer. 1994 Jun 1;73(11):2680-6 [8194005.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 Feb;59(3):313-20 [16770582.001]
  • [Cites] Cancer. 2001 Mar 1;91(5):918-27 [11251943.001]
  • [Cites] Ann Surg Oncol. 2001 Jul;8(6):519-24 [11456051.001]
  • [Cites] Br J Cancer. 2006 May 8;94(9):1281-6 [16622464.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Feb;30(2):288-95 [12552348.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • (PMID = 18373171.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Contrast Media; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 42
  •  go-up   go-down


6. Lima EM, Leal MF, Burbano RR, Khayat AS, Assumpção PP, Bello MJ, Rey JA, Smith MA, Casartelli C: Methylation status of ANAPC1, CDKN2A and TP53 promoter genes in individuals with gastric cancer. Braz J Med Biol Res; 2008 Jun;41(6):539-43
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylation status of ANAPC1, CDKN2A and TP53 promoter genes in individuals with gastric cancer.
  • Gastric cancer is the forth most frequent malignancy and the second most common cause of cancer death worldwide.
  • Many tumor genes are inactivated by DNA methylation in gastric cancer.
  • We evaluated the DNA methylation status of ANAPC1, CDKN2A and TP53 by methylation-specific PCR in 20 diffuse- and 26 intestinal-type gastric cancer samples and 20 normal gastric mucosa in individuals from Northern Brazil.
  • All gastric cancer samples were advanced stage adenocarcinomas.
  • Gastric samples were surgically obtained at the João de Barros Barreto University Hospital, State of Pará, and were stored at -80 degrees C before DNA extraction.
  • Patients had never been submitted to chemotherapy or radiotherapy, nor did they have any other diagnosed cancer.
  • None of the gastric cancer samples presented methylated DNA sequences for ANAPC1 and TP53.
  • CDKN2A methylation was not detected in any normal gastric mucosa; however, the CDKN2A promoter was methylated in 30.4% of gastric cancer samples, with 35% methylation in diffuse-type and 26.9% in intestinal-type cancers.
  • CDKN2A methylation was associated with the carcinogenesis process for ~30% diffuse-type and intestinal-type compared to non-neoplastic samples.
  • Thus, ANAPC1 and TP53 methylation was probably not implicated in gastric carcinogenesis in our samples.
  • CDKN2A can be implicated in the carcinogenesis process of only a subset of gastric neoplasias.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18622497.001).
  • [ISSN] 1414-431X
  • [Journal-full-title] Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas
  • [ISO-abbreviation] Braz. J. Med. Biol. Res.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / ANAPC1 protein, human; 0 / Apc1 Subunit, Anaphase-Promoting Complex-Cyclosome; EC 6.3.2.19 / Anaphase-Promoting Complex-Cyclosome; EC 6.3.2.19 / Ubiquitin-Protein Ligase Complexes
  •  go-up   go-down


7. Fujiwara Y, Taniguchi H, Kimura Y, Takiguchi S, Yasuda T, Yano M, Monden M: [Two advanced gastric cancer patients who showed malignant ileus soon after administration of combination therapy of preoperative intra-peritoneal chemotherapy and gastrectomy]. Gan To Kagaku Ryoho; 2003 Oct;30(11):1614-7
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two advanced gastric cancer patients who showed malignant ileus soon after administration of combination therapy of preoperative intra-peritoneal chemotherapy and gastrectomy].
  • Forty-eight patients with serosa-invaded advanced gastric cancer were administered to pre-operative intra-peritoneal chemotherapy to prevent peritoneal recurrence.
  • There were no severe adverse effects from the intra-peritoneal chemotherapy.
  • Of these patients, 2 showed malignant ileus shortly after intra-peritoneal chemotherapy and gastrectomy, and needed laparotomy because of dilatation of duodenum stump and liver dysfunction.
  • The intestines and mesothelium showed diffuse thickness and hardness.
  • We report the clinicopathological features of these cases and therapeutic limitation of intra-peritoneal chemotherapy.
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Gastrectomy. Ileus / etiology. Injections, Intraperitoneal / adverse effects. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Humans. Male. Middle Aged. Mitomycin / administration & dosage. Mitomycin / adverse effects. Neoplasm Invasiveness. Preoperative Care

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14619477.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


8. Krawczyk M, Mykała-Cieśla J, Kołodziej-Jaskuła A: Acanthosis nigricans as a paraneoplastic syndrome. Case reports and review of literature. Pol Arch Med Wewn; 2009 Mar;119(3):180-3
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Acanthosis nigricans (AN) is a skin disorder characterized by focal or diffuse hyperkeratosis symmetric hyperpigmentation of the skin and oral cavity mucosa.
  • Chemotherapy may cause regression of skin lesions.
  • Both have been associated with gastric adenocarcinoma.
  • In the first case skin lesions were sensitive to chemotherapy (until cancer progression), while in the second case treatment had to be discontinued because of cardiotoxity without regression of skin lesions.
  • [MeSH-major] Acanthosis Nigricans / complications. Acanthosis Nigricans / diagnosis. Adenocarcinoma / diagnosis. Adenocarcinoma / etiology. Stomach Neoplasms / diagnosis. Stomach Neoplasms / etiology

  • Genetic Alliance. consumer health - Acanthosis Nigricans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19514649.001).
  • [Journal-full-title] Polskie Archiwum Medycyny Wewnetrznej
  • [ISO-abbreviation] Pol. Arch. Med. Wewn.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 8
  •  go-up   go-down


9. Ichimura T, Chin K, Kobayashi K, Osaka M, Kuboki Y, Ogura M, Shinozaki E, Suenaga M, Matsuzaka S, Mizunuma N, Hatake K: [The incidence of gastrointestinal bleeding, thromboembolic events, and gastrointestinal perforation in metastatic or unresectable gastric cancer during chemotherapy]. Gan To Kagaku Ryoho; 2010 Nov;37(11):2131-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The incidence of gastrointestinal bleeding, thromboembolic events, and gastrointestinal perforation in metastatic or unresectable gastric cancer during chemotherapy].
  • The incidence of gastrointestinal bleeding, thromboembolic events and gastrointestinal perforation during chemotherapy with metastatic or unresectable gastric cancer has been unknown.
  • PATIENTS AND METHODS: We investigated metastatic or unresectable gastric cancer patients who received chemotherapy during January 2002 to December 2006.
  • Grade≥3 (CTCAE v3.0) adverse events from the first day of chemotherapy to 1 month after the last day of chemotherapy were investigated.
  • RESULTS: A total of 292 patients received chemotherapy.
  • Patient characteristics were as follows: median age 63.5 years (range, 28 to 87); performance status 0/1/2/3: 129/129/31/3; male: female, 206:86, histopathological type intestinal/diffuse/unclassified-adenocarcinoma/others: 91/139/58/4.
  • We should be aware of the frequency of these toxicities in the treatment of gastric cancer.
  • [MeSH-major] Gastrointestinal Hemorrhage / etiology. Intestinal Perforation / etiology. Stomach Neoplasms / drug therapy. Thromboembolism / etiology

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21084812.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


10. Takashima A, Shirao K, Hirashima Y, Takahari D, Okita NT, Nakajima TE, Kato K, Hamaguchi T, Yamada Y, Shimada Y: Sequential chemotherapy with methotrexate and 5-fluorouracil for chemotherapy-naive advanced gastric cancer with disseminated intravascular coagulation at initial diagnosis. J Cancer Res Clin Oncol; 2010 Feb;136(2):243-8
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential chemotherapy with methotrexate and 5-fluorouracil for chemotherapy-naive advanced gastric cancer with disseminated intravascular coagulation at initial diagnosis.
  • PURPOSE: Advanced gastric cancer (AGC) rarely presents with disseminated intravascular coagulation (DIC) at the time of diagnosis before treatment with no current standard chemotherapy (CTx) regimen.
  • We investigated the effectiveness of sequential CTx with methotrexate and 5-fluorouracil (MF) in chemotherapy-naive AGC patients with DIC.
  • RESULTS: From July 1999 to January 2007, 1,365 patients with unresectable or recurrent AGC received first-line CTx at the National Cancer Center Hospital in Tokyo, Japan.
  • Nineteen patients (86%) had histologically diffuse-type adenocarcinoma and 18 (82%) had bone metastasis.
  • The median time-to-treatment failure for AGC and overall survival were 98 days [95% confidence interval (CI), range 50-146 days] and 154 days (95% CI, range 126-180 days), respectively.
  • CONCLUSIONS: MF was an effective and well-tolerated regimen for improving DIC in chemotherapy-naive AGC patients with DIC; however, the prognosis of the patients remained poor even with improved DIC parameters.
  • [MeSH-major] Adenocarcinoma / complications. Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disseminated Intravascular Coagulation / etiology. Stomach Neoplasms / complications. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Antimetabolites, Antineoplastic / administration & dosage. Bone Neoplasms / complications. Bone Neoplasms / secondary. Female. Fluorouracil / administration & dosage. Humans. Male. Methotrexate / administration & dosage. Middle Aged. Retrospective Studies. Survival Analysis. Treatment Failure. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Fukuoka Igaku Zasshi. 1989 Oct;80(10):477-81 [2559010.001]
  • [Cites] Thromb Haemost. 2001 Sep;86(3):828-33 [11583315.001]
  • [Cites] Oncology. 1995 Nov-Dec;52(6):505-8 [7478440.001]
  • [Cites] Am J Hematol. 2000 Nov;65(3):215-22 [11074538.001]
  • [Cites] Cancer. 1993 Jun 15;71(12):3813-8 [8508349.001]
  • [Cites] Lancet Oncol. 2008 Mar;9(3):215-21 [18282805.001]
  • [Cites] N Engl J Med. 1999 Aug 19;341(8):586-92 [10451465.001]
  • [Cites] Anticancer Res. 2008 Mar-Apr;28(2B):1293-7 [18505068.001]
  • [Cites] Jpn J Clin Oncol. 2008 Jun;38(6):432-7 [18515821.001]
  • [Cites] Anticancer Res. 1994 May-Jun;14(3B):1277-9 [8067696.001]
  • [Cites] Thromb Haemost. 2003 Apr;89(4):660-5 [12669120.001]
  • [Cites] Thromb Diath Haemorrh. 1975 Sep 30;34(1):181-93 [171794.001]
  • [Cites] Science. 1979 Sep 14;205(4411):1135-7 [472732.001]
  • [Cites] Gastric Cancer. 2000 Aug 4;3(1):19-23 [11984704.001]
  • [Cites] Jpn J Clin Oncol. 2004 Jun;34(6):316-22 [15333683.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Oct;77(10):5663-7 [6160578.001]
  • [Cites] Gastric Cancer. 1999 May;2(1):52-56 [11957071.001]
  • [Cites] Isr Med Assoc J. 2006 Dec;8(12):853-5 [17214103.001]
  • [Cites] Jpn J Clin Oncol. 2000 Mar;30(3):122-5 [10798538.001]
  • [Cites] J Clin Oncol. 1994 May;12(5):960-9 [8164048.001]
  • [Cites] Gastric Cancer. 2001;4(4):212-8 [11846065.001]
  • [Cites] Am J Clin Oncol. 1998 Oct;21(5):452-7 [9781598.001]
  • [Cites] Zhonghua Yi Xue Za Zhi (Taipei). 1997 Mar;59(3):204-9 [9198298.001]
  • (PMID = 19727819.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


11. Yoshida M, Boku N, Ohtsu A, Muto M, Nagashima F, Yoshida S: Combination chemotherapy of irinotecan plus cisplatin for advanced gastric cancer: efficacy and feasibility in clinical practice. Gastric Cancer; 2001;4(3):144-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination chemotherapy of irinotecan plus cisplatin for advanced gastric cancer: efficacy and feasibility in clinical practice.
  • BACKGROUND: A previous phase II study showed that a combination of irinotecan (CPT-11) with cisplatin (CDDP) was effective for advanced gastric cancers, but was associated with substantial neutropenia and diarrhea.
  • METHODS: The subjects comprised 65 patients with advanced gastric cancer treated with CPT-11 (70mg/m2, day 1, day 15) and CDDP (80mg/m2, day 1) as first-line chemotherapy between April 1993 and March 1999.
  • Patient backgrounds, response rates, response durations, times to progression, and survival rates were investigated retrospectively.
  • There were no treatment-related or early deaths within 30 days from the last treatment day.
  • The median survival times of all patients, patients with an intestinal type of adenocarcinoma, and patients with a diffuse type were 365, 472, and 291 days, respectively.
  • Multivariate analysis showed that the histological type of cancer was a significant independent prognostic factor (P = 0.0169).
  • CONCLUSION: This retrospective study confirmed the efficacy and feasibility of this combination therapy in clinical practice.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11760080.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


12. Fujita T, Fukuda K, Nishi H, Takao T, Ohmura Y, Mano M, Komatsubara S, Yano T: [A case of effective response to TS-1 of inoperable gastric cancer, in the course of chemotherapy for malignant lymphoma]. Gan To Kagaku Ryoho; 2003 Nov;30(12):1977-81
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of effective response to TS-1 of inoperable gastric cancer, in the course of chemotherapy for malignant lymphoma].
  • We encountered a case of effective response to TS-1 of inoperable gastric cancer, in the course of chemotherapy for malignant lymphoma.
  • A 78-year-old man, in the course of chemotherapy for malignant lymphoma, complained of appetite loss.
  • A biopsy from gastric endoscopy indicated gastric carcinoma.
  • This was diagnosed as inoperable gastric cancer, and gastro-jejunostomy was performed.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Oxonic Acid / therapeutic use. Pyridines / therapeutic use. Stomach Neoplasms / drug therapy. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Drug Administration Schedule. Drug Combinations. Humans. Lymphatic Metastasis. Male

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14650971.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


13. Yamaki S, Iwata S, Ohtsuka K, Kitaoka A, Masumoto H, Katoh H: [A case report of curative resection for gastric cancer with peritoneal dissemination successfully treated by combined chemotherapy of S-1 and paclitaxel]. Gan To Kagaku Ryoho; 2008 May;35(5):821-3
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report of curative resection for gastric cancer with peritoneal dissemination successfully treated by combined chemotherapy of S-1 and paclitaxel].
  • The patient was a 54-year-old female with gastric cancer.
  • As laparotomy showed diffuse peritoneal dissemination, only laparotomy was performed and chemotherapy was conducted with a combination of S-1 80 mg/m(2) (2 weeks administration and 1 week rest) and paclitaxel (PTX) 50 mg/m(2) (day 1, 8).
  • The only adverse effect was grade 1 stomatitis during this chemotherapy.
  • The S-1/PTX combination chemotherapy was thought to be effective for gastric cancer with peritoneal dissemination and made curative operation possible in this case.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastrectomy. Peritoneal Neoplasms / pathology. Stomach Neoplasms / therapy
  • [MeSH-minor] Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Combined Modality Therapy. Drug Combinations. Female. Humans. Middle Aged. Oxonic Acid / administration & dosage. Paclitaxel / administration & dosage. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18487921.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


14. Adán-Merino L, Gómez-Senent S, Froilán-Torres C, Suárez J, Martín- Arranz E, Larrauri J, Mora-Sanz P, Segura-Cabral JM, Aldeguer-Martinez M: [Gastric adenocarcinoma in young adults; comparative study with older patients]. Rev Gastroenterol Mex; 2010;75(3):253-60
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastric adenocarcinoma in young adults; comparative study with older patients].
  • [Transliterated title] Adenocarcinoma gástrico en adultos jóvenes; estudio comparativo con pacientes mayores.
  • BACKGROUND: Gastric adenocarcinoma (GA) has been considered a disease of elderly age and has been rarely reported in patients younger than 35 years of age.
  • The aim of thisΩ demographic, clinicopathological and prognosis of gastric cancer in young patients and to compare their features with the behavior in elder adults.
  • Lauren diffuse type carcinoma was more frequent in people younger than 35 years (70%) than in older patients (17.4%).
  • Surgical resection was performed in 68% of cases and the rest received only systemic chemotherapy.
  • CONCLUSION: Gastric adenocarcinoma is rare in young patients and most cases presented at advanced clinical stage similar to elderly patients, so the prognosis in both age groups is poor.
  • For this reason is important to be aware of alarm symptoms and risk factors in order to perform an early endoscopic diagnosis and a treatment with curative intent.
  • [MeSH-major] Adenocarcinoma / epidemiology. Stomach Neoplasms / epidemiology
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Combined Modality Therapy. Databases, Factual. Female. Humans. Male. Mexico / epidemiology. Middle Aged. Retrospective Studies. Survival Analysis. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20959173.001).
  • [ISSN] 0375-0906
  • [Journal-full-title] Revista de gastroenterología de México
  • [ISO-abbreviation] Rev Gastroenterol Mex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


15. Wai HP, Yau TK, Sze WM, Yeung MW, Hioe F, Lee AW: Metastatic tumour of the tunica vaginalis testis from carcinoma of the stomach. Int J Clin Pract; 2000 Dec;54(10):685-6
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic tumour of the tunica vaginalis testis from carcinoma of the stomach.
  • A 50-year-old man with advanced inoperable gastric adenocarcinoma and diffuse peritoneal metastasis received six cycles of palliative chemotherapy and responded clinically with weight gain.
  • Two months after the completion of chemotherapy, however, he developed a left hydrocele.
  • Aspiration yielded 70 ml of yellowish hydrocele fluid, which contained metastatic adenocarcinoma cells, consistent with a gastric primary tumour.
  • Two weeks later, he developed a painful recurrent left hydrocele with increasing pain and swelling.
  • On microscopic examination, the tunica vaginalis showed reactive mesothelial hyperplasia and extensive lymphatic permeation by poorly differentiated adenocarcinoma, consistent with a gastric primary tumour.
  • [MeSH-major] Adenocarcinoma / secondary. Stomach Neoplasms. Testicular Hydrocele / etiology. Testicular Neoplasms / secondary

  • Genetic Alliance. consumer health - Stomach carcinoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11221287.001).
  • [ISSN] 1368-5031
  • [Journal-full-title] International journal of clinical practice
  • [ISO-abbreviation] Int. J. Clin. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


16. Nakayama N, Koizumi W, Tanabe S, Sasaki T, Saigenji K: A phase II study of combined chemotherapy with methotrexate, 5-fluorouracil, and low-dose cisplatin (MFP) for histologically diffuse-type advanced and recurrent gastric cancer (KDOG9501). Gastric Cancer; 2006;9(3):185-91
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of combined chemotherapy with methotrexate, 5-fluorouracil, and low-dose cisplatin (MFP) for histologically diffuse-type advanced and recurrent gastric cancer (KDOG9501).
  • BACKGROUND: Histologically diffuse-type gastric cancer is well known to have a poor prognosis and is often complicated with abdominal and pleural effusions.
  • We evaluated the efficacy of a low dose of cisplatin combined with methotrexate and 5-fluorouracil (MFP therapy) in diffuse-type advanced gastric cancer.
  • The median survival time was 211 days.
  • CONCLUSION: MFP therapy is useful for the management of diffuse-type inoperable and recurrent gastric cancer, even in patients with conditions such as pleural effusion, ascites, or lymphangitis carcinomatosa who have a poor prognosis or cannot eat solid food.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cisplatin / administration & dosage. Dose-Response Relationship, Drug. Female. Fluorouracil / administration & dosage. Humans. Male. Methotrexate / administration & dosage. Middle Aged. Neoplasm Staging. Pleural Effusion, Malignant / diagnosis. Pleural Effusion, Malignant / drug therapy. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer Clin Oncol. 1985 Nov;21(11):1321-4 [4076293.001]
  • [Cites] Cancer Treat Rep. 1986 Oct;70(10):1215-7 [3756943.001]
  • [Cites] Cancer. 1993 Jun 15;71(12):3813-8 [8508349.001]
  • [Cites] Eur J Cancer. 1994;30A(9):1263-9 [7999410.001]
  • [Cites] J Clin Oncol. 1992 Jun;10(6):912-22 [1375284.001]
  • [Cites] Eur J Cancer. 1994;30A(14):2091-3 [7857709.001]
  • [Cites] Eur J Cancer. 1990 Jan;26(1):63-5 [2138482.001]
  • [Cites] Gan To Kagaku Ryoho. 1992 Jul;19(7):946-53 [1626950.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Dec;83(23):8923-5 [3466165.001]
  • [Cites] Cancer Res. 1977 Jan;37(1):327-8 [830420.001]
  • [Cites] Cancer Treat Rep. 1984 Dec;68(12):1497-8 [6542449.001]
  • [Cites] Eur J Surg Oncol. 1987 Jun;13(3):203-6 [3036603.001]
  • [Cites] Anticancer Res. 1994 May-Jun;14(3B):1277-9 [8067696.001]
  • [Cites] Science. 1979 Sep 14;205(4411):1135-7 [472732.001]
  • [Cites] J Biol Chem. 1981 Feb 25;256(4):1695-704 [6161926.001]
  • [Cites] Gastric Cancer. 2000 Aug 4;3(1):19-23 [11984704.001]
  • [Cites] Jpn J Clin Oncol. 2004 Jun;34(6):316-22 [15333683.001]
  • [Cites] Ann Oncol. 1991 Nov-Dec;2(10):751-4 [1801881.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Oct;77(10):5663-7 [6160578.001]
  • [Cites] Am J Clin Oncol. 1983 Feb;6(1):35-8 [6682284.001]
  • [Cites] Gan To Kagaku Ryoho. 1987 Aug;14(8):2482-90 [3619460.001]
  • [Cites] Cancer. 1984 Jan 1;53(1):18-22 [6317158.001]
  • [Cites] Cancer Treat Rep. 1985 Apr;69(4):449-50 [4039628.001]
  • [Cites] Gastric Cancer. 1999 May;2(1):52-56 [11957071.001]
  • [Cites] Eur J Cancer Clin Oncol. 1983 Jun;19(6):717-20 [6683644.001]
  • [Cites] N Engl J Med. 1983 Nov 3;309(18):1094-104 [6353235.001]
  • [Cites] Cancer Res. 1995 Apr 1;55(7):1407-12 [7882343.001]
  • [Cites] Cancer Chemother Pharmacol. 1993;32(3):167-72 [8500219.001]
  • [Cites] Surg Oncol. 1992 Jun;1(3):215-21 [1341254.001]
  • [Cites] Gastric Cancer. 2001;4(4):212-8 [11846065.001]
  • [Cites] Cancer Chemother Pharmacol. 1989;24(1):67-8 [2720894.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2640-7 [7989939.001]
  • [Cites] Cancer Treat Rep. 1982 Sep;66(9):1713-7 [7116348.001]
  • [Cites] Cancer Res. 1973 Dec;33(12):3091-5 [4760525.001]
  • [Cites] Lancet. 1986 Feb 1;1(8475):256-8 [2868265.001]
  • (PMID = 16952036.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


17. Chin K, Fujimura M, Sekit N, Mikami K, Kamijima S, Suzuki H, Ichikawa T: [Case of malignant lymphoma of the prostate complicated with prostate adenocarcinoma]. Nihon Hinyokika Gakkai Zasshi; 2009 Nov;100(7):698-702
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case of malignant lymphoma of the prostate complicated with prostate adenocarcinoma].
  • Esophagogastroduodenoscopy revealed a huge ulcer in the stomach, and based on biopsy findings, he was pathologically diagnosed as having diffuse large B-cell type malignant lymphoma.
  • Histological findings revealed diffuse large B-cell type malignant lymphoma and moderately differentiated adenocarcinoma of the prostate.
  • The patient achieved complete response after eight cycles of combination chemotherapy with rituximab cyclophosphamide, adriamycin, vincristine and predonisolone.
  • At the same time of chemotherapy, androgen deprivation therapy was initiated.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy. Neoplasms, Multiple Primary. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Humans. Male. Prednisolone / administration & dosage. Remission Induction. Rituximab. Treatment Outcome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19999135.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  • [Number-of-references] 12
  •  go-up   go-down


18. Kaiser U, Zugmaier G, Frank M, Riedel I, Neubauer A, Moll R: [AFP-producing adenocarcinoma of the stomach. A rare tumor with poor prognosis]. Pathologe; 2003 Mar;24(2):141-5
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [AFP-producing adenocarcinoma of the stomach. A rare tumor with poor prognosis].
  • [Transliterated title] Das AFP-positive Adenokarzinom des Magens. Ein seltener Tumor mit früher Disseminierung.
  • A 27-year-old, previously healthy man with abdominal discomfort was diagnosed with a small gastric tumor of the cardia by means of gastroscopy.
  • Further staging revealed diffuse hepatic metastases and enlarged mediastinal lymph nodes.
  • Biopsies taken from the gastric tumor and one of the hepatic metastases revealed a poorly differentiated adenocarcinoma (grade 3) with papillary and small solid areas and frequent clear cells.
  • The diagnosis of an AFP-producing adenocarcinoma of the stomach was made.
  • In spite of intensive combination chemotherapy the patient succumbed to his disease 3 months after diagnosis.
  • The rare AFP-producing adenocarcinoma of the stomach is characterised by a distinct morphology and immunohistochemistry.
  • The prognosis for an AFP-positive adenocarcinoma is poor.
  • [MeSH-major] Liver Neoplasms / secondary. Stomach Neoplasms / pathology. alpha-Fetoproteins / analysis
  • [MeSH-minor] Adult. Biomarkers, Tumor / blood. Fatal Outcome. Humans. Male. Neoplasm Staging. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Pathologe. 2003 May;24(3):213
  • (PMID = 12673505.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / alpha-Fetoproteins
  •  go-up   go-down


19. Tagami K, Tanda S, Tokumura H, Yamaguchi M: [A case of triple malignant tumors consisting of esophagus, stomach and malignant lymphoma with a histopathological feature of collision between gastric cancer and malignant lymphoma--a case report]. Gan To Kagaku Ryoho; 2010 Dec;37(13):2891-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of triple malignant tumors consisting of esophagus, stomach and malignant lymphoma with a histopathological feature of collision between gastric cancer and malignant lymphoma--a case report].
  • We report a rare case of a collision between a gastric cancer and a malignant lymphoma with a wide systemic metastasis, combined with esophagus cancer, stomach cancer and malignant lymphoma.
  • He was diagnosed with malignant diffuse large B cell lymphoma by immunostaining from the extirpated right testis.
  • He received six cycles of R-CHOP therapy.
  • Thereafter, we performed MTX-HOPE therapy as a salvage therapy for four cycles.
  • During this chemotherapy, he felt epigastralgia; esophagus cancer (squamous cell carcinoma) and stomach cancer (highly-differentiated adenocarcinoma) were found by upper endoscopy.
  • However, the gastrointestinal cancer was inoperable, since the malignant lymphoma was progressive.
  • Pathological examination revealed that the adenocarcinoma had partly collided with the malignant lymphoma.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Esophageal Neoplasms / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Neoplasms, Multiple Primary / pathology. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160264.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


20. Yeh JS, Munn SE, Plunkett TA, Harper PG, Hopster DJ, du Vivier AW: Coexistence of acanthosis nigricans and the sign of Leser-Trélat in a patient with gastric adenocarcinoma: a case report and literature review. J Am Acad Dermatol; 2000 Feb;42(2 Pt 2):357-62
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexistence of acanthosis nigricans and the sign of Leser-Trélat in a patient with gastric adenocarcinoma: a case report and literature review.
  • The association of acanthosis nigricans (AN) with the sign of Leser-Trélat (LT) and gastric carcinoma is rare.
  • Our patient was a 69-year-old man, who presented with hematemesis; a stage-IV poorly differentiated, diffuse-type, adenocarcinoma of the gastric antrum was diagnosed.
  • AN and the sign of LT predated tumor detection by 6 months and regressed after chemotherapy in parallel with reduction of the tumor load, demonstrating the dermatoses as paraneoplastic phenomena.
  • The patient died 7 months after completion of chemotherapy.
  • [MeSH-major] Acanthosis Nigricans / diagnosis. Adenocarcinoma / diagnosis. Keratosis, Seborrheic / diagnosis. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Aged. Fatal Outcome. Gastric Mucosa / pathology. Humans. Male. Mouth Mucosa / pathology. Skin / pathology

  • Genetic Alliance. consumer health - Acanthosis Nigricans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10640933.001).
  • [ISSN] 0190-9622
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 50
  •  go-up   go-down


21. Takiuchi H, Hirata I, Kawabe S, Egashira Y, Katsu K: Immunohistochemical expression of vascular endothelial growth factor can predict response to 5-fluorouracil and cisplatin in patients with gastric adenocarcinoma. Oncol Rep; 2000 Jul-Aug;7(4):841-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of vascular endothelial growth factor can predict response to 5-fluorouracil and cisplatin in patients with gastric adenocarcinoma.
  • The combination of 5-fluorouracil (5-FU) and cisplatin is used most commonly for gastric carcinoma.
  • Recent studies have indicated that vascular endothelial growth factor (VEGF) is related to drug delivery through angiogenesis and vascular permeability.
  • In this study, we evaluated the efficacy and toxicity of continuous infusion of 5-FU and low dose cisplatin infusion as first-line treatment in patients with unresectable gastric adenocarcinoma.
  • We also examined the relationship between chemotherapy response and immunohistochemical expression of VEGF in the biopsy samples of gastric primary.
  • This treatment was repeated weekly for 3 consecutive weeks.
  • Patients with intestinal histologic type (10/12) and good performance status ([PS], 13/18) showed good response rate (83.3%, and 72.2%, respectively) compared to patients with diffuse histologic type (4/18) and poor PS [(1/12) 22.2%, and 8.
  • Multivarite analysis revealed that VEGF-positive and good PS had a significant impact on chemotherapy response in this treatment.
  • Continuous infusion of 5-FU and low dose cisplatin infusion is an effective treatment for patients with unresectable gastric carcinoma, and VEGF expression may be a useful predictor of chemotherapy response in this regimen.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endothelial Growth Factors / analysis. Lymphokines / analysis. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Aged. Biopsy. Cisplatin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Immunohistochemistry. Infusions, Intravenous. Male. Middle Aged. Multivariate Analysis. Predictive Value of Tests. Survival Rate. Time Factors. Vascular Endothelial Growth Factor A. Vascular Endothelial Growth Factors

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10854555.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] GREECE
  • [Chemical-registry-number] 0 / Endothelial Growth Factors; 0 / Lymphokines; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factors; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


22. Santini D, Vincenzi B, Fratto ME, Perrone G, Lai R, Catalano V, Cass C, Ruffini PA, Spoto C, Muretto P, Rizzo S, Muda AO, Mackey JR, Russo A, Tonini G, Graziano F: Prognostic role of human equilibrative transporter 1 (hENT1) in patients with resected gastric cancer. J Cell Physiol; 2010 May;223(2):384-8
SciCrunch. DrugBank: Data: Chemical .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic role of human equilibrative transporter 1 (hENT1) in patients with resected gastric cancer.
  • Nucleoside transporter proteins are specialized proteins that mediate the transport of nucleosides and nucleoside analog drugs across the plasma membrane.
  • The hENT1 expression has been demonstrated to be related with prognosis and activity of gemcitabine-based therapy in breast, ampullary, lung, and pancreatic cancer.
  • We investigated the immunohistochemical expression of hENT in tumor samples from 111 patients with resected gastric adenocarcinoma, correlating these data with clinical parameters and disease outcomes.
  • None of the patients received chemotherapy or radiation therapy before or after surgery as a part of an adjuvant or neoadjuvant program.
  • Furthermore, considering only patients with diffuse or mixed tumors and lymph-node positive, the expression of hENT1 was strongly related with DFS and OS.
  • Immunohistochemistry for the hENT1 protein carries prognostic information in patients with resected gastric cancer and holds promise as a predictive factor in chemotherapy decisions.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Equilibrative Nucleoside Transporter 1 / metabolism. Gastric Mucosa / metabolism. Stomach Neoplasms / diagnosis. Stomach Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / metabolism. Antineoplastic Agents / pharmacokinetics. Cohort Studies. Disease Progression. Disease-Free Survival. Drug Resistance, Neoplasm / physiology. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Metastasis / physiopathology. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / prevention & control. Predictive Value of Tests. Prognosis. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20082300.001).
  • [ISSN] 1097-4652
  • [Journal-full-title] Journal of cellular physiology
  • [ISO-abbreviation] J. Cell. Physiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Equilibrative Nucleoside Transporter 1; 0 / SLC29A1 protein, human
  •  go-up   go-down


23. Okines AF, Cunningham D: Trastuzumab in gastric cancer. Eur J Cancer; 2010 Jul;46(11):1949-59
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trastuzumab in gastric cancer.
  • Trastuzumab is a fully humanised monoclonal antibody directed at the human epidermal growth factor receptor-2 (HER-2) which has been a component of standard therapy for advanced and resected HER-2-positive breast cancers for almost a decade.
  • HER-2 over-expression, defined as HER-2 protein over-expression using immunohistochemistry scored as 3+ and/or erbB-2 amplification detected by fluorescent in situ hybridisation, was detected in 22.1% of 3807 patients with advanced gastric and oesophagogastric junction (OGJ) adenocarcinoma screened for eligibility for the phase III ToGA study.
  • The validated scoring system for HER-2 positivity in gastric cancers differs from that recommended for breast cancer due to an increased frequency of incomplete membranous immunoreactivity and heterogeneity of HER-2 expression in gastric cancers.
  • The highest rates of HER-2 over-expression are observed in patients with OGJ rather than gastric tumours and intestinal-type rather than diffuse or mixed histology.
  • The international multicentre randomised phase III ToGA study assessed the addition of trastuzumab to a cisplatin plus fluoropyrimidine (FP) chemotherapy doublet for patients with HER-2-positive advanced gastric or OGJ adenocarcinoma.
  • Trastuzumab plus FP chemotherapy is now the standard of care for patients with advanced gastric and OGJ cancers which over-express HER-2.
  • Further research to evaluate trastuzumab delivered beyond progression, in combination with alternative first-line chemotherapy regimens, and in the perioperative and adjuvant setting is urgently needed.
  • Additionally, research into mechanisms of resistance and strategies to overcome primary or acquired resistance to trastuzumab must now be expedited, using lessons learnt over the past decade in HER-2-positive breast cancer to maximise the benefit from this agent.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Clinical Trials, Phase III as Topic. Forecasting. Genes, erbB-2. Humans. Multicenter Studies as Topic. Quinazolines / therapeutic use. Randomized Controlled Trials as Topic. Receptor, ErbB-2. Trastuzumab

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20542421.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Quinazolines; 0VUA21238F / lapatinib; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab
  •  go-up   go-down


24. Lisenko Y, Kumar AJ, Yao J, Ajani J, Ho L: Leptomeningeal carcinomatosis originating from gastric cancer: report of eight cases and review of the literature. Am J Clin Oncol; 2003 Apr;26(2):165-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leptomeningeal carcinomatosis originating from gastric cancer: report of eight cases and review of the literature.
  • Leptomeningeal carcinomatosis caused by metastatic gastric adenocarcinoma has been rarely reported in the United States.
  • We present eight cases of patients with gastric cancer who subsequently developed meningeal carcinomatosis.
  • Distinguishing features include a predominance of poorly differentiated histology, typically associated with signet ring cells, a diffuse pattern of primary organ involvement, systemic dissemination in the form of peritoneal carcinomatosis, and development of LMD despite responsiveness to chemotherapy elsewhere in the body.
  • The natural history of these patients, with or without treatment, was uniformly poor.
  • Although previously thought to be an extremely rare event, LMD in the setting of gastric adenocarcinoma may be a problem on the rise, possibly due to the increasing survival times of patients.
  • Furthermore, the striking clinical picture of patients with LMD raises interesting questions about the biology and metastatic behavior of certain subclasses of gastric cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / secondary. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12714889.001).
  • [ISSN] 0277-3732
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 20
  •  go-up   go-down


25. Chandanos E, Lindblad M, Rubio CA, Jia C, Warner M, Gustafsson JA, Lagergren J: Tamoxifen exposure in relation to gastric adenocarcinoma development. Eur J Cancer; 2008 May;44(7):1007-14
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tamoxifen exposure in relation to gastric adenocarcinoma development.
  • Epidemiological research has indicated that the anti-oestrogen tamoxifen, used in breast cancer therapy, may increase the risk of gastric adenocarcinoma of the intestinal but not of the diffuse type.
  • The study participants comprised women in the county of Stockholm who in the Swedish Cancer Register were first recorded with breast cancer and subsequently gastric cancer during the period January 1958-August 2005.
  • Tumour material was reviewed histologically to verify gastric adenocarcinoma diagnosis and classify these cancers into intestinal or diffuse type.
  • Amongst 68 women with verified gastric adenocarcinoma, 30 had been treated with tamoxifen and 38 not.
  • The intestinal type of gastric adenocarcinoma was not more frequent amongst tamoxifen users (27%) than amongst non-users (34%) (p=0.601).
  • There were no material differences between the tamoxifen groups regarding distribution of any of the three ERs of the intestinal adenocarcinoma specimens.
  • Tamoxifen users had a shorter latency between breast cancer and gastric adenocarcinoma (4 versus 13 years) which was similar in the intestinal and diffuse types.
  • This study does not support the hypothesis that tamoxifen increases the isolated risk of the intestinal type, but it indicates that tamoxifen use might accelerate the tumour progression or increase the overall risk of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / chemically induced. Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Stomach Neoplasms / chemically induced. Tamoxifen / adverse effects
  • [MeSH-minor] Adult. Age of Onset. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Cohort Studies. Disease Progression. Female. Gastric Mucosa / metabolism. Humans. Middle Aged. Receptors, Estrogen / metabolism. Risk Factors. Stomach / metabolism. Sweden

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18394879.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


26. Ueda Y, Yamagishi H, Yamashita T, Itoh N, Itoi H, Shirasaka T, Ajani JA: S-1-induced, prolonged complete regression of lung metastasis from gastric cancer refractory to 5'-DFUR: a case report with pharmacokinetic study. Jpn J Clin Oncol; 2004 May;34(5):282-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] S-1-induced, prolonged complete regression of lung metastasis from gastric cancer refractory to 5'-DFUR: a case report with pharmacokinetic study.
  • S-1 is an oral fluoropyrimidine reported to be most active for gastric cancer.
  • However, few studies have documented a complete response (CR) of lung metastasis to S-1 treatment.
  • We describe a 66-year-old woman in whom S-1 induced complete regression of lung metastasis from gastric cancer, that had been refractory to another oral fluoropyrimidine, 5'-deoxy-5-fluorouridine (5'-DFUR).
  • After preoperative chemotherapy with a combination of etoposide, adriamycin and cisplatin and with methotrexate plus 5-fluorouracil, the patient underwent a total gastrectomy with lower esophagectomy for advanced diffuse-type gastric cancer with invasion of the esophagus in May 1993.
  • She received postoperative adjuvant chemotherapy with 5'-DFUR (600 mg/day) for 3 years.
  • Chemotherapy with 5'-DFUR was reinitiated after operation, but re-metastasis to the left lung with elevation of the serum carcinoembryonic antigen (CEA) level was diagnosed in June 1999.
  • Treatment with S-1 was started in August.
  • S-1 was given orally in a dose of 100 mg/day for 28 consecutive days, followed by a 14-day recovery; treatment was repeated every 6 weeks.
  • This may be the first report to document a prolonged complete response of lung metastasis from gastric cancer induced by single-agent chemotherapy with S-1.
  • [MeSH-major] Adenocarcinoma, Mucinous / secondary. Antimetabolites, Antineoplastic / pharmacokinetics. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Oxonic Acid / pharmacokinetics. Pyridines / pharmacokinetics. Stomach Neoplasms / pathology. Tegafur / pharmacokinetics
  • [MeSH-minor] Administration, Oral. Chemotherapy, Adjuvant. Drug Administration Schedule. Drug Combinations. Esophagectomy. Female. Floxuridine / administration & dosage. Fluorouracil / blood. Gastrectomy. Humans. Middle Aged. Radiography, Thoracic. Remission Induction. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLOXURIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15231865.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Pyridines; 039LU44I5M / Floxuridine; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; U3P01618RT / Fluorouracil; V1JK16Y2JP / doxifluridine
  •  go-up   go-down


27. Kawai H, Ohtsu A, Boku N, Hamamoto Y, Nagashima F, Muto M, Sano Y, Mera K, Yano T, Doi T, Yoshida S: Efficacy and safety profile of S-1 in patients with metastatic gastric cancer in clinical practice: results from a post-marketing survey. Gastric Cancer; 2003;6 Suppl 1:19-23
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety profile of S-1 in patients with metastatic gastric cancer in clinical practice: results from a post-marketing survey.
  • BACKGROUND: S-1(TS-1), a novel oral fluoropyrimidine, has been commercially available for gastric cancer in Japan.
  • The aim of this analysis was to evaluate the efficacy and safety profile of this agent in clinical practice for patients with advanced gastric cancer registered in the postmarketing survey from our institution.
  • METHODS: Between April 1999 and April 2000, a total of 51 chemo-naive patients were registered in the survey from the National Cancer Center Hospital East.
  • RESULTS: Of the 51 patients, 41 (80%) fulfilled the criteria of the guidelines determined by the company as appropriate patients for the drug administration.
  • The median number of treatment courses was five.
  • Toxicities were generally mild: grade 3 or 4 toxicities were seen in 10% or fewer patients, and no treatment-related deaths occurred.
  • With a minimum follow-up of 2 years, median survival time and 2-year survival were 11.1 months and 33%, respectively.
  • The majority of the 17 2-year survivors had diffuse-type histology and peritoneal metastasis and achieved an objective response.
  • CONCLUSION: S-1 appears to be safe and highly active, with favorable longterm survival in patients with metastatic gastric cancer, particularly in those with diffuse-type histology and peritoneal metastasis.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Oxonic Acid / therapeutic use. Product Surveillance, Postmarketing. Pyridines / therapeutic use. Stomach Neoplasms / drug therapy. Tegafur / therapeutic use
  • [MeSH-minor] Adult. Aged. Drug Combinations. Drug Evaluation. Female. Humans. Japan. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary. Survival Analysis. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gan To Kagaku Ryoho. 2001 Oct;28(10):1381-90 [11681245.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):54-9 [12506170.001]
  • [Cites] Br J Cancer. 2000 Jul;83(2):141-5 [10901361.001]
  • [Cites] Br J Cancer. 1995 Mar;71(3):587-91 [7533517.001]
  • [Cites] Gastric Cancer. 2000 Dec 27;3(3):145-150 [11984728.001]
  • [Cites] Anticancer Drugs. 1996 Jul;7(5):548-57 [8862723.001]
  • [Cites] Cancer. 1993 Jul 1;72(1):37-41 [8508427.001]
  • [Cites] Oncology. 2000 Apr;58(3):191-7 [10765119.001]
  • [Cites] Gastric Cancer. 2001;4(3):144-9 [11760080.001]
  • [Cites] Eur J Cancer. 1998 Oct;34(11):1715-20 [9893658.001]
  • [Cites] Ann Oncol. 1994 Feb;5(2):189-90 [8186165.001]
  • [Cites] Gastric Cancer. 2001;4(4):212-8 [11846065.001]
  • [Cites] Br J Cancer. 2001 Sep 28;85(7):939-43 [11592762.001]
  • (PMID = 12775015.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


28. Lang SA, Gaumann A, Koehl GE, Seidel U, Bataille F, Klein D, Ellis LM, Bolder U, Hofstaedter F, Schlitt HJ, Geissler EK, Stoeltzing O: Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int J Cancer; 2007 Apr 15;120(8):1803-10
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model.
  • The mammalian target of rapamycin (mTOR) has become an interesting target for cancer therapy through its influence on oncogenic signals, which involve phosphatidylinositol-3-kinase and hypoxia-inducible factor-1alpha (HIF-1alpha).
  • Since mTOR is an upstream regulator of HIF-1alpha, a key mediator of gastric cancer growth and angiogenesis, we investigated mTOR activation in human gastric adenocarcinoma specimens and determined whether rapamycin could inhibit gastric cancer growth in mice.
  • Expression of phospho-mTOR was assessed by immunohistochemical analyses of human tissues.
  • For in vitro studies, human gastric cancer cell lines were used to determine S6K1, 4E-BP-1 and HIF-1alpha activation and cancer cell motility upon rapamycin treatment.
  • Immunohistochemical analyses showed strong expression of phospho-mTOR in 60% of intestinal- and 64% of diffuse-type human gastric adenocarcinomas.
  • In vitro, rapamycin-treatment effectively blocked S6K1, 4E-BP-1 and HIF-1alpha activation, and significantly impaired tumor cell migration.
  • In vivo, rapamycin-treatment led to significant inhibition of subcutaneous tumor growth, decreased CD31-positive vessel area and reduced tumor cell proliferation.
  • Similar significant results were obtained in an orthotopic model of gastric cancer.
  • In the dorsal-skin-fold chamber model, rapamycin-treatment significantly inhibited tumor vascularization in vivo.
  • In conclusion, mTOR is frequently activated in human gastric cancer and represents a promising new molecular target for therapy.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Disease Models, Animal. Neovascularization, Pathologic / prevention & control. Protein Kinases / metabolism. Sirolimus / therapeutic use. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Animals. Cell Hypoxia. Cell Line, Tumor. Cell Movement / drug effects. Cell Proliferation / drug effects. Humans. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Intestinal Neoplasms / drug therapy. Intestinal Neoplasms / metabolism. Intestinal Neoplasms / pathology. Male. Mice. Mice, Inbred BALB C. Mice, Nude. Phosphatidylinositol 3-Kinases / metabolism. Phosphorylation / drug effects. Ribosomal Protein S6 Kinases, 70-kDa / metabolism. Signal Transduction. Survival Rate. TOR Serine-Threonine Kinases. Vascular Endothelial Growth Factor A / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17230506.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Vascular Endothelial Growth Factor A; EC 2.7.- / Protein Kinases; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.1.1 / mTOR protein, mouse; EC 2.7.11.1 / Ribosomal Protein S6 Kinases, 70-kDa; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


29. Lee HS, Cheung DY, Kim JI, Cho SH, Park SH, Han JY, Kim JK: A case of spontaneous regression of advanced gastric cancer. J Korean Med Sci; 2010 Oct;25(10):1518-21
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of spontaneous regression of advanced gastric cancer.
  • Esopahgogastroduodenoscopy showed the diffuse infiltrative type of gastric cancer encircling from the cardia to the lower body.
  • On abdominal computerized tomography, the gastric wall was diffusely thickened with overlying mucosal enhancement without lymph node involvement.
  • Histologic examination revealed poorly differentiated adenocarcinoma.
  • On esophagogastroduodenoscopy, the gastric mucosa of the body looked normal without any dysplastic change.
  • Abdominal CT revealed a decreased thickening of the gastric wall of the body.
  • [MeSH-major] Adenocarcinoma / diagnosis. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Aged, 80 and over. Diabetes Mellitus / drug therapy. Endoscopy, Gastrointestinal. Humans. Hypoglycemic Agents / therapeutic use. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Endocrinol. 2007 Jun;156(6):617-21 [17535860.001]
  • [Cites] Acta Obstet Gynecol Scand. 2008;87(12):1296-300 [18951206.001]
  • [Cites] Urol Int. 2001;66(2):119-20 [11223759.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2000;12(5):335-6 [11315723.001]
  • [Cites] Scand J Urol Nephrol. 2002;36(5):396-8 [12487751.001]
  • [Cites] Immunity. 2004 Aug;21(2):137-48 [15308095.001]
  • [Cites] Abdom Imaging. 2005 Nov-Dec;30(6):734-7 [16252150.001]
  • [Cites] Med J Aust. 1980 Feb 9;1(3):136-7 [6990211.001]
  • [Cites] J Surg Oncol. 1981;17(3):201-9 [6166811.001]
  • [Cites] Dig Dis Sci. 1981 Nov;26(11):1045-50 [6271517.001]
  • [Cites] Acta Oncol. 1990;29(5):545-50 [2206563.001]
  • [Cites] Br J Haematol. 1994 Nov;88(3):621-2 [7819077.001]
  • [Cites] Ann Hematol. 1996 Oct;73(4):189-93 [8890708.001]
  • [Cites] N Engl J Med. 1972 Nov 16;287(20):1013-7 [4650967.001]
  • (PMID = 20890436.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Hypoglycemic Agents
  • [Other-IDs] NLM/ PMC2946665
  • [Keywords] NOTNLM ; Advanced Gastric Cancer / Neoplasm Regression, Spontaneous
  •  go-up   go-down


30. Kamoshida S, Shiogama K, Shimomura R, Inada K, Sakurai Y, Ochiai M, Matuoka H, Maeda K, Tsutsumi Y: Immunohistochemical demonstration of fluoropyrimidine-metabolizing enzymes in various types of cancer. Oncol Rep; 2005 Nov;14(5):1223-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical demonstration of fluoropyrimidine-metabolizing enzymes in various types of cancer.
  • Fluoropyrimidines [5-Fluorouracil (5-FU) and its prodrugs] have been widely used in the treatment of solid cancers.
  • The anticancer effects primarily depend on intratumoral levels of enzymes metabolizing the drugs, such as dihydropyrimidine dehydrogenase (DPD), orotate phosphoribosyltransferase (OPRT), thymidine phosphorylase (TP), and thymidylate synthase (TS).
  • In order to know the tumor types susceptible to respective fluoropyrimidines, we investigated the expression of DPD, OPRT, TP and TS in various types of cancer with the immunoperoxidase method.
  • These four enzymes existed in all of the cancer types studied, such as pulmonary, gastric, colorectal, hepatic, cholecystic, pancreatic, renal, urocystic, and mammary cancers.
  • Respective types of cancers presented characteristic immunohistochemical features as follows: pulmonary adenocarcinoma, DPD- and TP-high; pulmonary squamous cell carcinoma, TS- and TP-high; intestinal-type gastric adenocarcinoma, TP-high; diffuse-type gastric adenocarcinoma, DPD-low and TS-high; colorectal adenocarcinoma, DPD- and TP-low, hepatocellular carcinoma, DPD-high, and TS- and OPRT-low; cholecystic adenocarcinoma, DPD- and TS-high; renal cell carcinoma, DPD-low, and OPRT- and TP-high; urocystic transitional cell carcinoma, DPD-high and OPRT-low; and mammary ductal carcinoma, OPRT-low, and TS- and TP-high.
  • The enzyme expression pattern in cancer tissue was generally similar to that of their normal counterparts.
  • However, TP immunoreactivity in adenocarcinomas of the lung, stomach and gallbladder, and urothelial carcinoma of the urinary bladder was stronger, and DPD immunoreactivity in adenocarcinoma of the breast was weaker, when compared with normal epithelial cells.
  • These results indicated that the key enzymes influencing the effects of fluoropyrimidines differ from cancer to cancer.
  • Fluoropyrimidine treatment may be selected, based on the simultaneous immunohistochemical evaluation of the fluoropyrimidine metabolic enzymes.
  • [MeSH-major] Antimetabolites, Antineoplastic / metabolism. Antimetabolites, Antineoplastic / pharmacology. Fluorouracil / metabolism. Fluorouracil / pharmacology. Neoplasms / drug therapy. Neoplasms / enzymology
  • [MeSH-minor] Dihydrouracil Dehydrogenase (NADP) / metabolism. Drug Resistance. Humans. Immunohistochemistry. Orotate Phosphoribosyltransferase / metabolism. Thymidine Phosphorylase / metabolism. Thymidylate Synthase / metabolism

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16211289.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; EC 1.3.1.2 / Dihydrouracil Dehydrogenase (NADP); EC 2.1.1.45 / Thymidylate Synthase; EC 2.4.2.10 / Orotate Phosphoribosyltransferase; EC 2.4.2.4 / Thymidine Phosphorylase; U3P01618RT / Fluorouracil
  •  go-up   go-down


31. Nagashima F, Boku N, Ohtsu A, Yoshida S, Hasebe T, Ochiai A, Sakata Y, Saito H, Miyata Y, Hyodo I, Ando M: Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with irinotecan and cisplatin. Jpn J Clin Oncol; 2005 Dec;35(12):714-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with irinotecan and cisplatin.
  • BACKGROUND: Previously we reported that immunohistochemical examination of p53, bcl-2, glutathione S-transferase-pi (GST-pi), thymidylate synthase (TS) and vascular endothelial growth factor (VEGF) in biopsy samples was a useful method for predicting clinical outcome of gastric cancer patients treated with 5-fluorouracil and cisplatin.
  • Here, we investigated if these biological markers can predict chemoresponse and survival of unresectable gastric cancer patients treated with irinotecan and cisplatin.
  • METHODS: The subjects were 55 unresectable gastric cancer patients treated with irinotecan (70 mg/m(2), Days 1 and 15) and cisplatin (80 mg/m(2), Day 1).
  • RESULTS: The overall response rate and the median survival time were 55% (30/55) and 321 days, respectively.
  • Thirty patients with intestinal-type adenocarcinoma survived longer than 25 patients with diffuse-type (median survival time: 446, 259 days, P = 0.013).
  • The 39 patients having 2 or 3 favorable phenotypes (p53-negative, bcl-2-negative and VEGF-positive) survived longer than the remaining 16 patients (median survival time: 444, 259 days, P = 0.021).
  • In the Cox model, the number of the favorable phenotypes showed a tendency to correlate with survival after adjustment for potentially prognostic factors such as histological type or performance status (P = 0.070).
  • CONCLUSIONS: Immunohistochemical examination of biological markers may be useful in predicting the clinical outcome of unresectable gastric cancer patients treated with irinotecan and cisplatin.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Cisplatin / administration & dosage. Drug Administration Schedule. Female. Glutathione S-Transferase pi / analysis. Humans. Male. Middle Aged. Predictive Value of Tests. Prognosis. Proto-Oncogene Proteins c-bcl-2 / analysis. Tumor Suppressor Protein p53 / analysis. Vascular Endothelial Growth Factor A / analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16303791.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; 0 / Vascular Endothelial Growth Factor A; 7673326042 / irinotecan; EC 2.5.1.18 / Glutathione S-Transferase pi; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


32. Rha SY, Jeung HC, Roh JK, Kim JJ, Noh SH, Min JS, Kim BS, Chung HC: Biological phenotype determination with ex vivo model in gastric cancer for matrix-metalloproteinase inhibitor treatment. Int J Mol Med; 2002 Sep;10(3):251-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biological phenotype determination with ex vivo model in gastric cancer for matrix-metalloproteinase inhibitor treatment.
  • Among the many biological characteristics of cancer, matrix-metalloproteinases (MMPs) are essential for tumor invasion and metastasis.
  • To test the possibility of ex vivo model as a therapeutic guideline for MMP inhibitor (MMPI) treatment, we evaluated IC50 of the gabexate mesylate against MMP-9.
  • Thirty-four paired normal and gastric cancer tissues were tested to measure the IC50 of the gabexate mesylate.
  • Both MMP-9 expression (p=0.04) and IC50 (p=0.02) were higher in cancer than normal tissues.
  • IC50 of the cancer tissues was higher than paired normal tissues especially in cases with large tumor (> or =5 cm) (p=0.03), higher T-stage (p=0.04), lymph node metastasis (p=0.04) and advanced stage (p=0.04).
  • In cancers extending beyond submucosa or in diffuse/mixed type, a tendency of higher IC50 was observed than tumors confined to submucosa or intestinal type cancer despite similar MMP-9 activity between the groups.
  • This model can be applied in detecting patients with poor prognosis and patients who may benefit from MMPI treatment.
  • [MeSH-major] Enzyme Inhibitors / pharmacology. Matrix Metalloproteinase Inhibitors. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Age Factors. Aged. Aged, 80 and over. Cell Differentiation. Female. Gabexate / pharmacology. Humans. Inhibitory Concentration 50. Male. Matrix Metalloproteinases / pharmacology. Middle Aged. Multivariate Analysis. Phenotype. Prognosis. Serine Proteinase Inhibitors / pharmacology. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12165796.001).
  • [ISSN] 1107-3756
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Matrix Metalloproteinase Inhibitors; 0 / Serine Proteinase Inhibitors; 4V7M9137X9 / Gabexate; EC 3.4.24.- / Matrix Metalloproteinases
  •  go-up   go-down


33. Ramos-De la Medina A, Salgado-Nesme N, Torres-Villalobos G, Medina-Franco H: Clinicopathologic characteristics of gastric cancer in a young patient population. J Gastrointest Surg; 2004 Mar-Apr;8(3):240-4
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic characteristics of gastric cancer in a young patient population.
  • The aim of this study was to analyze the clinicopathologic characteristics of young patients with gastric cancer with special attention to hereditary gastric cancer in a tertiary referral university hospital.
  • Charts from all patients 40 years of age or younger at the time of diagnosis, during the period from January 1, 1987 to December 31, 2001, were retrospectively reviewed.
  • Demographic variables, family history of gastric cancer, clinicopathologic characteristics, and treatment-related variables were analyzed.
  • During the study period, 558 cases of gastric cancer were seen at our institution, 83 (14.8%) were in patients 40 years of age or younger.
  • Fourteen patients (16.9%) had a family history of gastric cancer.
  • Five patients (6%) fulfilled the criteria of hereditary gastric cancer.
  • On univariate analysis, advanced tumor stage, hypoalbuminemia, low performance status, diffuse type, pangastric tumor location, noncurative surgery, and lack of adjuvant chemotherapy had a significant negative impact on survival.
  • On multivariate analysis, advanced tumor stage, pangastric tumor location, and absence of adjuvant chemotherapy were significantly associated with poor prognosis.
  • Family history of gastric cancer or hereditary gastric cancer did not have any impact on prognosis.
  • There is a high frequency of gastric cancer in young patients at our institution.
  • Family history of gastric cancer or hereditary gastric cancer did not have a significant impact on survival.
  • Complete resection and adjuvant chemotherapy appeared to confer the only chance of prolonged survival.
  • [MeSH-major] Adenocarcinoma / genetics. Neoplastic Syndromes, Hereditary / diagnosis. Stomach Neoplasms / genetics
  • [MeSH-minor] Adult. Cadherins / genetics. Female. Humans. Male. Mexico / epidemiology. Multivariate Analysis. Neoplasm Staging. Retrospective Studies. Stomach / pathology. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 1982 Sep-Oct;2(5):283-6 [7165284.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1092-9 [12006524.001]
  • [Cites] Ann Surg Oncol. 2000 Aug;7(7):515-9 [10947020.001]
  • [Cites] Eur J Cancer Prev. 1999 Jul;8(3):223-7 [10443951.001]
  • [Cites] Surg Gynecol Obstet. 1980 Jun;150(6):883-6 [7376053.001]
  • [Cites] Ann Surg. 1988 Nov;208(5):593-6 [2847662.001]
  • [Cites] Rev Gastroenterol Mex. 1990 Jan-Mar;55(1):17-24 [2291062.001]
  • [Cites] Am J Surg Pathol. 1998 Sep;22(9):1125-31 [9737246.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1994 Jan-Feb;3(1):15-8 [8118379.001]
  • [Cites] Br Med J. 1965 Jun 19;1(5450):1577-83 [14288125.001]
  • [Cites] Cancer. 1960 Mar-Apr;13:379-85 [13836790.001]
  • [Cites] N Engl J Med. 2000 Jul 13;343(2):78-85 [10891514.001]
  • [Cites] Cancer. 1992 Apr 1;69(7):1645-50 [1312889.001]
  • [Cites] J Am Coll Surg. 1999 Jan;188(1):22-6 [9915238.001]
  • [Cites] Surg Gynecol Obstet. 1986 Apr;162(4):343-8 [3961656.001]
  • [Cites] Cancer. 2001 Feb 15;91(4):863-8 [11241256.001]
  • [Cites] Ann Surg Oncol. 2000 Jun;7(5):346-51 [10864341.001]
  • [Cites] J Am Coll Surg. 2002 Aug;195(2):181-6; discussion 186-7 [12168964.001]
  • [Cites] Am J Clin Oncol. 2002 Feb;25(1):84-9 [11823704.001]
  • [Cites] Ann Surg. 2003 Mar;237(3):319-34 [12616115.001]
  • [Cites] J Clin Epidemiol. 2003 Jan;56(1):1-9 [12589864.001]
  • [Cites] Int J Cancer. 1993 Jun 19;54(4):594-606 [8514451.001]
  • [Cites] West J Med. 1991 Feb;154(2):172-4 [2006563.001]
  • [Cites] J Pathol. 1997 Aug;182(4):404-13 [9306961.001]
  • (PMID = 15019915.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cadherins
  •  go-up   go-down


34. Louvet C, Carrat F, Mal F, Mabro M, Beerblock K, Vaillant JC, Cady J, André T, Gamelin E, de Gramont A: Prognostic factor analysis in advanced gastric cancer patients treated with hydroxyurea, leucovorin, 5-fluorouracil, and cisplatin (HLFP regimen). Cancer Invest; 2003;21(1):14-20
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factor analysis in advanced gastric cancer patients treated with hydroxyurea, leucovorin, 5-fluorouracil, and cisplatin (HLFP regimen).
  • This study was performed to determine the prognostic factors of 102 nonresectable locally advanced or metastatic gastric cancer patients prospectively treated with a multimodulation of 5-fluorouracil (5FU), hydroxyurea, leucovorin, and cisplatin.
  • Median times for progression-free survival and overall survival were eight and 11 months, respectively.
  • Response rate and survival in patients with gastric linitis or diffuse forms were in the same range as in patients with intestinal forms of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Alopecia / chemically induced. Biomarkers, Tumor / blood. Carcinoembryonic Antigen / blood. Cisplatin / administration & dosage. Cisplatin / adverse effects. Disease-Free Survival. Drug Evaluation. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Gastrointestinal Diseases / chemically induced. Hematologic Diseases / chemically induced. Humans. Hydroxyurea / administration & dosage. Hydroxyurea / adverse effects. Karnofsky Performance Status. Kidney Diseases / chemically induced. Leucovorin / administration & dosage. Life Tables. Liver Neoplasms / epidemiology. Liver Neoplasms / secondary. Male. Middle Aged. Nervous System Diseases / chemically induced. Prognosis. Proportional Hazards Models. Quality of Life. Risk Factors. Survival Analysis. Treatment Outcome. Weight Gain

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12643005.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; X6Q56QN5QC / Hydroxyurea; HLFP regimen
  •  go-up   go-down


35. Pandey M, Kumar V, Shukla M, Kumar M: Thyroid swelling in a 32-year-old male. BMJ Case Rep; 2009;2009

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fine-needle aspiration cytology from the thyroid swelling revealed deposits from the mucinous adenocarcinoma.
  • The further diagnostic and metastatic work-up identified a diffuse carcinoma of the stomach as the primary site with liver as secondary and retroperitoneal lymph nodes having mucinous deposits with associated Peutz-Jeghers polyposis.
  • This is the first report in the English literature of intrathyroidal metastasis from carcinoma of the stomach with Peutz-Jeghers polyposis presenting primarily as a thyroid swelling.
  • Preoperative diagnosis, proper evaluation and high degree of suspicion may avoid unnecessary thyroidectomy and effective palliation can be achieved with chemotherapy in view of disseminated disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg Oncol. 2004 Aug;30(6):583-8 [15256229.001]
  • [Cites] Langenbecks Arch Surg. 2006 Nov;391(6):581-7 [16983577.001]
  • [Cites] Anticancer Res. 2008 Sep-Oct;28(5B):2885-8 [19031929.001]
  • [Cites] Cancer. 1997 Feb 1;79(3):574-8 [9028370.001]
  • [Cites] Ann Intern Med. 1998 Jun 1;128(11):896-9 [9634427.001]
  • [Cites] World J Surg. 1999 Feb;23(2):177-80; discussion 181 [9880428.001]
  • [Cites] Am J Pathol. 1999 Jan;154(1):127-35 [9916927.001]
  • (PMID = 21686341.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3028274
  •  go-up   go-down


36. Lazăr D, Tăban S, Sporea I, Dema A, Cornianu M, Lazăr E, Goldiş A, Vernic C: Ki-67 expression in gastric cancer. Results from a prospective study with long-term follow-up. Rom J Morphol Embryol; 2010;51(4):655-61
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ki-67 expression in gastric cancer. Results from a prospective study with long-term follow-up.
  • AIM: The analysis of immunohistochemical expression of the Ki-67 antigen using the monoclonal antibody MIB1 in 61 patients with gastric cancer, the correlation with clinicopathological factors and the prognosis of the patients.
  • The tumor cells were considered Ki-67 positive in the presence of brown nuclear staining of granular or diffuse type.
  • RESULTS: In the gastric carcinomas, we remarked various Ki-67 scores.
  • For a proper grouping of the results, we classified gastric carcinomas into two categories: carcinomas with high MI Ki-67 (≥45%) and carcinomas with low MI Ki-67 (≤45%).
  • We noticed an increased frequency of high MI Ki-67 carcinomas in elderly patients (p=0.03) and also in the tumors developed at cardia level and those extended in the entire stomach in the moment of diagnosis (p<0.001).
  • The histological forms associated to high Ki-67 values are represented by the anaplastic carcinoma (100% of cases) and papillary adenocarcinoma (60% of cases).We observed a close correlation between the degree of tumor differentiation and the Ki-67 score (p<0.001).
  • The results of our study do not reveal any correlation between the Lauren's Classification of gastric carcinomas, the lymphovascular invasion, the depth of tumor invasion, the TNM stage and the Ki-67 score (p>0.05).
  • CONCLUSIONS: In our study, immunohistochemical assessment of the tumor proliferation does not represent a prognostic factor, but seems to be useful in identifying of a group of patients with aggressive tumors, needing adjuvant postoperatory chemotherapy.
  • [MeSH-major] Ki-67 Antigen / metabolism. Stomach Neoplasms / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21103622.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


37. Yoon SN, Roh SA, Cho DH, Kim MB, Hyun YL, Ro S, Kim BS, Kim SY, Kim YS, Kim JC: In vitro chemosensitivity of gastric adenocarcinomas to histone deacetylase inhibitors, compared to established drugs. Hepatogastroenterology; 2010 May-Jun;57(99-100):657-62
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro chemosensitivity of gastric adenocarcinomas to histone deacetylase inhibitors, compared to established drugs.
  • BACKGROUND/AIMS: This study was performed to determine the efficacy of histone deacetylase inhibitors in gastric cancer, together with other established regimens.
  • METHODOLOGY: The chemosensitivities of 93 gastric cancer patients to established drugs, and three histone deacetylase inhibitors (SAHA, PXD101, and a novel candidate, CG-2) were evaluated using the histoculture drug response assay.
  • Synergistic activity was evident with most combinations of established drugs and histone deacetylase inhibitors.
  • Diffuse- or mixed-type carcinomas on Lauren classification were closely associated with increased chemosensitivity to TS-1 (p = 0.044).
  • Node-positive and "other than tubular type" tumors on WHO classification were chemosensitive to cisplatin (p = 0.011 and 0.014, respectively).
  • CONCLUSIONS: This in vitro chemosensitivity assay validates the comparable chemo-response of gastric cancers to histone deacetylase inhibitors and established drugs, indicating considerable therapeutic efficacy of these agents.
  • [MeSH-major] Adenocarcinoma / drug therapy. Histone Deacetylase Inhibitors / pharmacology. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cell Proliferation / drug effects. Female. Humans. In Vitro Techniques. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20698245.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Histone Deacetylase Inhibitors
  •  go-up   go-down


38. Waguri N, Furukawa K, Shobugawa K, Takizawa K, Ikeda H, Iwamoto Y, Aiba T, Yoneyama O, Igarashi K, Tsukioka S, Yabe M, Kuwabara S, Shibuya H: [A case of gastric cancer with abdominal wall invasion treated by weekly low-dose paclitaxel therapy]. Gan To Kagaku Ryoho; 2006 Aug;33(8):1151-4
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of gastric cancer with abdominal wall invasion treated by weekly low-dose paclitaxel therapy].
  • Here we report a case of gastric cancer with diffuse abdominal wall invasion treated with weekly low-dose paclitaxel therapy.
  • Computed tomography revealed diffuse swelling of the abdominal wall and hydronephrosis of the right kidney.
  • Upper gastrointestinal endoscopy demonstrated type 3' advanced gastric cancer.
  • Pathological diagnosis of both gastric tumor and abdominal wall biopsy specimens was poorly-differentiated adenocarcinoma containing signet ring cell carcinoma.
  • Abdominal wall swelling like cuirass disappeared after 2 courses of low-dose paclitaxel therapy.
  • Nine repeated courses of this regimen have been given until now; the relapse of the abdominal wall invasion has not become apparent, and primary gastric lesion has been a stable disease.
  • Diffuse abdominal wall invasion of gastric cancer like cuirass without ascites is a rare condition, and low-dose paclitaxel was very effective for this condition.
  • [MeSH-major] Abdominal Wall / pathology. Adenocarcinoma / drug therapy. Antineoplastic Agents, Phytogenic / administration & dosage. Paclitaxel / administration & dosage. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Carcinoma, Signet Ring Cell / pathology. Drug Administration Schedule. Humans. Male. Middle Aged. Neoplasm Invasiveness. Radiography, Abdominal. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16912538.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


39. Ohno T, Yokoyama Y, Aihara R, Mochiki E, Asao T, Kuwano H: Sudden bilateral sensorineural hearing loss as the presenting symptom of meningeal carcinomatosis of gastric cancer: report of a case. Surg Today; 2010 Jun;40(6):561-5
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sudden bilateral sensorineural hearing loss as the presenting symptom of meningeal carcinomatosis of gastric cancer: report of a case.
  • Meningeal carcinomatosis is the diffuse infiltration of the meninges by metastatic carcinoma.
  • Upper gastrointestinal endoscopy revealed a large type 3 gastric cancer, and the pathological diagnosis was poorly differentiated adenocarcinoma.
  • Although combination chemotherapy with oral S-1 and weekly paclitaxel and radiation therapy were performed, the patient's condition gradually worsened, and he eventually died 12 weeks after the onset of deafness.
  • [MeSH-major] Adenocarcinoma / secondary. Hearing Loss, Bilateral / etiology. Hearing Loss, Sensorineural / etiology. Hearing Loss, Sudden / etiology. Meningeal Carcinomatosis / secondary. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Sensorineural hearing loss.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Otol. 1992 Jul;13(4):369-71 [1415503.001]
  • [Cites] Br J Cancer. 2006 Dec 18;95(12):1642-7 [17133268.001]
  • [Cites] J Clin Oncol. 1987 Oct;5(10):1655-62 [3309199.001]
  • [Cites] J Clin Neurosci. 2005 Apr;12(3):315-8 [15851093.001]
  • [Cites] Brain Nerve. 2007 Dec;59(12):1385-9 [18095490.001]
  • [Cites] Curr Treat Options Oncol. 2001 Dec;2(6):517-27 [12057097.001]
  • [Cites] N Engl J Med. 1973 Oct 11;289(15):770-3 [4517004.001]
  • [Cites] Otolaryngol Head Neck Surg. 1992 Jan;106(1):92-7 [1734379.001]
  • [Cites] J R Coll Surg Edinb. 1998 Apr;43(2):119-21 [9621540.001]
  • [Cites] J Clin Oncol. 1986 Jan;4(1):68-73 [3079822.001]
  • [Cites] Cancer. 1982 Feb 15;49(4):759-72 [6895713.001]
  • [Cites] Lancet Oncol. 2008 Mar;9(3):215-21 [18282805.001]
  • [Cites] Arch Neurol. 1996 Jul;53(7):626-32 [8929170.001]
  • [Cites] Arch Neurol. 1974 Feb;30(2):122-37 [4405841.001]
  • [Cites] Otolaryngol Head Neck Surg. 2001 May;124(5):592-4 [11337674.001]
  • [Cites] Cancer Treat Rev. 1999 Apr;25(2):103-19 [10395835.001]
  • [Cites] Surg Today. 2008;38(12):1102-7 [19039635.001]
  • [Cites] Neurol Sci. 2005 Feb;25(6):345-7 [15729499.001]
  • [Cites] Surg Today. 2008;38(5):445-8 [18560969.001]
  • (PMID = 20496139.001).
  • [ISSN] 1436-2813
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


40. Tepes B: Can gastric cancer be prevented? J Physiol Pharmacol; 2009 Dec;60 Suppl 7:71-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can gastric cancer be prevented?
  • Gastric adenocarcinoma is the fourth most common malignancy worldwide and is globally the second leading cause of cancer-related deaths each year.
  • Among the risk factors are genetic factors (genetic diffuse gastric cancer - E-cadherin mutation (CDH1), pro- and anti-inflammatory cytokine genes and innate immune response gene polymorphisms), environmental factors (infection with the bacterium Helicobacter pylori (H. pylori), Epstein-Barr virus, nutrition: nitroso compounds, salt and antioxidants intake) and other factors (pernicious anemia, gastric polyps, gastric surgery, reproductive hormones, smoking).
  • The bacterium H. pylori has been found to be the major carcinogen in gastric cancer development.
  • Approximately 65%-80% of non-cardia gastric adenocarcinoma is attributable to H. pylori infection.
  • One percent of patients infected with H. pylori will develop gastric cancer.
  • American and European guidelines on the management of H. pylori infection recommend H. pylori eradication in all patients with atrophy and/or intestinal metaplasia and in all first-degree relatives of gastric cancer patients.
  • In the Asian Pacific Gastric Cancer Consensus, it was suggested for the first time that it is time for population-based screening and treatment of H. pylori infection in regions with gastric cancer incidence above 20/100000 per year.
  • Population screen and treat of H. pylori infection should be recommended in regions with gastric cancer incidence above 20/100000 per year.
  • This can be a good approach in H. pylori infected patients before they develop premalignant gastric lesions.
  • [MeSH-major] Adenocarcinoma / prevention & control. Stomach Neoplasms / prevention & control
  • [MeSH-minor] Animals. Early Detection of Cancer. Helicobacter Infections / complications. Helicobacter Infections / drug therapy. Helicobacter Infections / physiopathology. Helicobacter pylori. Humans. Mass Screening. Patient Education as Topic. Risk Factors. Stomach Diseases / physiopathology. Stomach Diseases / prevention & control. Stomach Diseases / therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20388948.001).
  • [ISSN] 1899-1505
  • [Journal-full-title] Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
  • [ISO-abbreviation] J. Physiol. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 74
  •  go-up   go-down


41. Amoroso V, Pittiani F, Grisanti S, Valcamonico F, Simoncini E, Ferrari VD, Marini G: Osteoblastic flare in a patient with advanced gastric cancer after treatment with pemetrexed and oxaliplatin: implications for response assessment with RECIST criteria. BMC Cancer; 2007;7:94
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteoblastic flare in a patient with advanced gastric cancer after treatment with pemetrexed and oxaliplatin: implications for response assessment with RECIST criteria.
  • CASE PRESENTATION: A 43 year-old man with advanced gastric cancer was enrolled in a phase II trial where he was treated with pemetrexed 500 mg/m2 plus oxaliplatin 120 mg/m2 every 3 weeks.
  • At first re-evaluation, the target lesions showed partial response and the non-target lesions showed complete response, but new diffuse osteoblastic lesions appeared.
  • The investigator decided to continue treatment until the second re-evaluation.
  • CONCLUSION: The appearance of osteoblastic lesions after an active antitumor treatment, a phenomenon known as flare, can complicate the definition of the best overall response using RECIST criteria.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Bone Neoplasms / secondary. Lung Neoplasms / secondary. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Glutamates / administration & dosage. Guanine / administration & dosage. Guanine / analogs & derivatives. Humans. Lymphatic Metastasis. Male. Organoplatinum Compounds / administration & dosage. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / secondary. Pemetrexed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. PEMETREXED .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] J Clin Oncol. 2004 Jun 15;22(12):2395-403 [15197201.001]
  • [Cites] Clin Orthop Relat Res. 2004 Jun;(423):208-12 [15232450.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2942-53 [15254062.001]
  • [Cites] Eur J Cancer. 2006 May;42(8):1031-9 [16616487.001]
  • [Cites] AJR Am J Roentgenol. 1979 Jun;132(6):927-31 [108971.001]
  • [Cites] Bone. 1992;13 Suppl 1:S57-62 [1581121.001]
  • [Cites] J Clin Oncol. 1995 May;13(5):1123-8 [7537797.001]
  • [Cites] Cancer Treat Rev. 1996 Jul;22(4):289-331 [9025785.001]
  • [Cites] Oncology. 1978;35(6):274-6 [745811.001]
  • (PMID = 17540044.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glutamates; 0 / Organoplatinum Compounds; 04Q9AIZ7NO / Pemetrexed; 04ZR38536J / oxaliplatin; 5Z93L87A1R / Guanine
  • [Other-IDs] NLM/ PMC1896169
  •  go-up   go-down


42. Nakamura T, Yamasaki K, Morikawa S, Ohnita K, Taura K, Isomoto H, Mizuta Y, Murase K, Murata I, Kohno S: [A case report of advanced gastric cancer responding to TS-1, a novel oral fluorouracil derivative]. Gan To Kagaku Ryoho; 2002 Jun;29(6):927-32
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report of advanced gastric cancer responding to TS-1, a novel oral fluorouracil derivative].
  • We report one case of advanced gastric cancer with lung and lymph node metastases that completely responded to TS-1.
  • A diagnosis of advanced gastric cancer with extensive lymph node metastases and multiple pulmonary metastases was made.
  • After 1 drug-free week, the second course was administered with 120 mg/body/day of TS-1 for 4 weeks.
  • After two courses, the primary tumor was reduced to an ulcer scar with pathological confirmation of a complete disappearance of the cancer tissue.
  • Moreover, computed tomography (CT) showed a complete regression of the extensive lymph node and diffuse lung metastases, for a complete response (CR).
  • The serum level of CEA was reduced from 172.7 ng/ml to 8.1 ng/ml after TS-1 treatment.
  • [MeSH-major] Adenocarcinoma, Papillary / drug therapy. Antineoplastic Agents / administration & dosage. Oxonic Acid / administration & dosage. Pyridines / administration & dosage. Stomach Neoplasms / drug therapy. Tegafur / administration & dosage
  • [MeSH-minor] Administration, Oral. Aged. Carcinoembryonic Antigen / blood. Drug Combinations. Female. Humans. Lung Neoplasms / secondary. Lymphatic Metastasis

  • Genetic Alliance. consumer health - Oral cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12090046.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Carcinoembryonic Antigen; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


43. Jadvar H, Tatlidil R, Garcia AA, Conti PS: Evaluation of recurrent gastric malignancy with [F-18]-FDG positron emission tomography. Clin Radiol; 2003 Mar;58(3):215-21
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of recurrent gastric malignancy with [F-18]-FDG positron emission tomography.
  • AIM: We retrospectively assessed the use of [(18)F] fluorodeoxyglucose positron emission tomography (FDG PET) in the evaluation of recurrent disease in patients with history of gastric malignancy.
  • MATERIALS AND METHODS: Eighteen patients were referred for FDG PET for evaluation of recurrent gastric cancer.
  • Prior treatments included total (n = 4) or partial gastrectomy (n = 14) followed by chemotherapy alone (n = 7) or combined chemoradiation therapy (n = 2).
  • The interval between the most recent treatment and PET ranged from 3 months to 2 years.
  • RESULTS: PET was concordant with computed tomography (CT) in 12 patients (5 TP, 6 TN, 1 FN).
  • PET-detected diffuse metastatic lesions in three of these patients with rising serum tumour markers while other imaging studies were negative.
  • Additional chemotherapy was initiated in these three patients (17% of total) based on PET localization of disease.
  • PET and a gastric anastomosis biopsy were negative in another patient with positive CT.
  • The remaining two patients without correlative imaging studies died shortly after positive PET studies with presumed recurrent cancer.
  • CONCLUSION: FDG PET may be useful in the evaluation of recurrent gastric cancer, and can localize the disease when CT is non-diagnostic.
  • Imaging evaluation with PET may also impact on the clinical management of patients with recurrent gastric cancer.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Fluorodeoxyglucose F18. Leiomyosarcoma / radionuclide imaging. Neoplasm Recurrence, Local / radionuclide imaging. Radiopharmaceuticals. Stomach Neoplasms / radionuclide imaging
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Retrospective Studies. Tomography, Emission-Computed / methods. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 The Royal College of Radiologists
  • [ErratumIn] Clin Radiol. 2003 Jul;58(7):570
  • (PMID = 12639527.001).
  • [ISSN] 0009-9260
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down






Advertisement